1. Phase II, 2‐stage, 2‐arm, PIK3CA mutation stratified trial of MK‐2206 in recurrent endometrial cancer. Issue 2 (13th December 2019) Authors: Myers, Andrea P.; Konstantinopoulos, Panagiotis A.; Barry, William T.; Luo, Weixiu; Broaddus, Russell R.; Makker, Vicky; Drapkin, Ronny; Liu, Joyce; Doyle, Austin; Horowitz, Neil S.; Meric‐Bernstam, Funda; Birrer, Michael; Aghajanian, Carol; Coleman, Robert L.; Mills, Gordon B.; Cantley, Lewis C.... Journal: International journal of cancer Issue: Volume 147:Issue 2(2020) Page Start: 413 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Toward Improving Practices for Submission of Diagnostic Tissue Blocks for National Cancer Institute Clinical Trials. Issue 2 (15th October 2019) Authors: Makhlouf, Hala; Watson, Mark A; Lankes, Heather A; Weil, Carol; Dickler, Maura; Birrer, Michael; Moskaluk, Christopher; Ramirez, Nilsa C; Okby, Nader; Alonsozana, Edgar; Barnes, Mark; Goldman, Edward B; Enos, Rebecca; Lubensky, Irina Journal: American journal of clinical pathology Issue: Volume 153:Issue 2(2020) Page Start: 149 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair‐Deficient Endometrial Cancer and a Germline BRCA1 Mutation. (22nd February 2018) Authors: Dizon, Don S.; Dias‐Santagata, Dora; Bregar, Amy; Sullivan, Laura; Filipi, Jennifer; DiTavi, Elizabeth; Miller, Lucy; Ellisen, Leif; Birrer, Michael; DelCarmen, Marcela Journal: Oncologist Issue: Volume 23:Number 6(2018) Page Start: 650 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 2022-RA-660-ESGO Characterization of extended treatment benefit from three phase 1 and 3 clinical trials examining patients with folate receptor alpha-positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine. (20th October 2022) Authors: Oaknin, Ana; Lorusso, Domenica; Oza, Amit; Colombo, Nicoletta; van Gorp, Toon; O'Malley, David; Banerjee, Susana; Murphy, Conleth; Harter, Philipp; Konecny, Gottfried; Kaminsky, Marie-Christine; Method, Michael; Wang, Jiuzhou; Coleman, Robert L; Birrer, Michael; Matulonis, Ursula; Moore, Kathleen Journal: International journal of gynecological cancer Issue: Volume 32(2022)Supplement 2 Page Start: A251 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Role of Molecular Agents and Targeted Therapy in Clinical Trials for Women With Ovarian Cancer. Issue 4 (1st April 2011) Authors: Ledermann, Jonathan A.; Marth, Christian; Carey, Mark S.; Birrer, Michael; Bowtell, David D.L.; Kaye, Stan; McNeish, Iain; Oza, Amit; Scambia, Giovanni; Rustin, Gordon; Stehman, Frederick B.; Gershenson, David; Thomas, Gillian; Berns, Els; Casado, Antonio; Ottevanger, Nelleke; Hilpert, Felix; Kim... Journal: International journal of gynecological cancer Issue: Volume 21:Issue 4(2011) Page Start: 763 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Targeting NaPi2b in ovarian cancer. (January 2023) Authors: Banerjee, Susana; Drapkin, Ronny; Richardson, Debra L.; Birrer, Michael Journal: Cancer treatment reviews Issue: Volume 112(2023) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer. Issue 3 (March 2017) Authors: Gockley, Allison; Melamed, Alexander; Bregar, Amy J.; Clemmer, Joel T.; Birrer, Michael; Schorge, John O.; del Carmen, Marcela G.; Rauh-Hain, J. Alejandro Journal: Obstetrics and gynecology Issue: Volume 129:Issue 3(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors. Issue 4 (19th October 2018) Authors: Elias, Kevin M; Tsantoulis, Petros; Tille, Jean‐Christophe; Vitonis, Allison; Doyle, Leona A; Hornick, Jason L; Kaya, Gurkan; Barnes, Laurent; Cramer, Daniel W; Puppa, Giacomo; Stuckelberger, Sarah; Hooda, Jagmohan; Dietrich, Pierre‐Yves; Goggins, Michael; Kerr, Candace L; Birrer, Michael; Hirsch... Journal: Journal of pathology Issue: Volume 246:Issue 4(2018) Page Start: 459 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. (17th March 2021) Authors: Wenzel, Lari; Osann, Kathryn; McKinney, Chelsea; Cella, David; Fulci, Giulia; Scroggins, Mary J; Lankes, Heather A; Wang, Victoria; Nephew, Kenneth P; Maxwell, George L; Mok, Samuel C; Conrads, Thomas P; Miller, Austin; Mannel, Robert S; Gray, Heidi J; Hanjani, Parviz; Huh, Warner K; Spirtos, Nic... Journal: Journal of the National Cancer Institute Issue: Volume 113:Number 10(2021) Page Start: 1369 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Issue 4 (April 2019) Authors: Konstantinopoulos, Panagiotis A; Barry, William T; Birrer, Michael; Westin, Shannon N; Cadoo, Karen A; Shapiro, Geoffrey I; Mayer, Erica L; O'Cearbhaill, Roisin E; Coleman, Robert L; Kochupurakkal, Bose; Whalen, Christin; Curtis, Jennifer; Farooq, Sarah; Luo, Weixiu; Eismann, Julia; Buss, Mary K;... Journal: Lancet oncology Issue: Volume 20:Issue 4(2019) Page Start: 570 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗